Dr Ailsa Holroyd

Honorary Clinical Lecturer (School of Cancer Sciences)

email: Ailsa.Holroyd@glasgow.ac.uk

Institute of Cancer Sciences, Paul O'Gorman Leukaemia Research Centre, 21 Shelley Road, Gartnavel General Hospital, G12 0ZD

Import to contacts

https://orcid.org/0000-0001-8687-5286

Publications

List by: Type | Date

Jump to: 2022 | 2019 | 2018 | 2015

Number of items: 5.

2022

Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)

2019

Hay, J. , Gilroy, K., Huser, C. , Kilbey, A., Mcdonald, A., MacCallum, A., Holroyd, A. , Cameron, E. and Neil, J. C. (2019) Collaboration of MYC and RUNX2 in lymphoma simulates T‐cell receptor signaling and attenuates p53 pathway activity. Journal of Cellular Biochemistry, 120(10), pp. 18332-18345. (doi: 10.1002/jcb.29143) (PMID:31257681) (PMCID:PMC6772115)

Cosimo, E. et al. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25(5), pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036) (PMID:30559170) (PMCID:PMC6398589)

2018

Holroyd, A. K. and Michie, A. M. (2018) The role of mTOR-mediated signaling in the regulation of cellular migration. Immunology Letters, 196, pp. 74-79. (doi: 10.1016/j.imlet.2018.01.015) (PMID:29408410)

2015

Nakagawa, R. et al. (2015) Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC subversion induces up-regulation of PKC II expression in B lymphocytes. Haematologica, 100(4), pp. 499-510. (doi: 10.3324/haematol.2014.112276) (PMID:25616575) (PMCID:PMC4380723)

This list was generated on Mon Dec 4 23:04:42 2023 GMT.

Jump to: Articles

Number of items: 5.

Articles

Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)

Hay, J. , Gilroy, K., Huser, C. , Kilbey, A., Mcdonald, A., MacCallum, A., Holroyd, A. , Cameron, E. and Neil, J. C. (2019) Collaboration of MYC and RUNX2 in lymphoma simulates T‐cell receptor signaling and attenuates p53 pathway activity. Journal of Cellular Biochemistry, 120(10), pp. 18332-18345. (doi: 10.1002/jcb.29143) (PMID:31257681) (PMCID:PMC6772115)

Cosimo, E. et al. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25(5), pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036) (PMID:30559170) (PMCID:PMC6398589)

Holroyd, A. K. and Michie, A. M. (2018) The role of mTOR-mediated signaling in the regulation of cellular migration. Immunology Letters, 196, pp. 74-79. (doi: 10.1016/j.imlet.2018.01.015) (PMID:29408410)

Nakagawa, R. et al. (2015) Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC subversion induces up-regulation of PKC II expression in B lymphocytes. Haematologica, 100(4), pp. 499-510. (doi: 10.3324/haematol.2014.112276) (PMID:25616575) (PMCID:PMC4380723)

This list was generated on Mon Dec 4 23:04:42 2023 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

Elucidating the role of mTor kinase signalling in chronic lymphocytic leukaemia
The Kay Kendall Leukaemia Fund
2014 - 2018